ABSTRACT SCID mice reconstituted with adult human peripheral blood leukocytes (hu-PBL-SCID mice) make antigen-specific human antibody responses following secondary immunization and can be infected with human immunodeficiency virus 1 (HIV-1), suggesting that they might prove useful for evaluating protective immunity to HIV-1 following vaccination of PBL donors. HIV-seronegative volunteers were immunized with vaccinia expressing HIV-lLAV1l/Br. 160 (14, 15) . hu-PBL-SCID mice established by using tetanus-immune PBL donors produced a tetanus-specific secondary human antibody response (10), suggesting that hu-PBL-SCID mice derived from HIV-1 immune donors might mount a specific immune response to HIV-1. We have generated hu-PBL-SCID mice by using PBLs from donors immunized with 160-kDa glycoprotein (gpl60) subunit vaccines and challenged the resulting mice with a high dose of HIV-1. hu-PBL-SCID mice derived from three of four vaccinees who had been primed with recombinant vaccinia virus expressing gp160 and booster injected with recombinant gp160 protein (rgp160) were resistant to challenge with homologous strains of HIV-1. The level of immunity adoptively transferred to hu-PBL-SCID mice (i.e., the fraction of challenged mice resistant to infec- 
envelope glycoprotein (vaccinia gpl60) and subsequently given booster injections of recombinant gpl60 protein (rgpl6O).
Their PBLs were used at intervals of 4-72 weeks after booster uijections to construct hu-PBL-SCII) mice, which were then challenged with 102-103 minimal animal infectious doses of highly homologous HIV-lmn. Control hu-PBL-SCID mice were constructed from donors receiving vaccinia, alum, or hepatitis B vaccine. Protection against virus infection was dermed as the absence of HIV-1 by culture and no detection of proviral genomes following PCR amplification. Control animals were highly susceptible to HIV infection. By contrast, hu-PBL-SCID mice reconstituted with cells from three of four donors immunized with vaccinia gpl60 and recently inijected with rgpl6O showed no evidence of HIV-1 infection by culture or PCR assays. With increasing time after rgpl60 iajection, the ability of vaccinee-derived hu-PBL-SCID mice to resist HIV-1 infection diminished. These results demonstrate that a potentially protective human immune response was stimulated by this HIV gp160 immunization protocol and show the utility of the hu-PBL-SCID model in the rapid evaluation of candidate vaccines.
Development of a safe, effective vaccine represents the best approach to preventing the spread of AIDS. Evaluation of candidate vaccines to human immunodeficiency virus (HIV) has to date been limited to studies of protective immunity in chimpanzees (1) (2) (3) (4) (5) and phase I trials of the safety and immunogenicity of candidate subunit vaccines in humans (6) (7) (8) (9) . These studies have shown various degrees of immunogenicity in humans and limited protection of chimpanzees. Development of a model to assess the relative protective immunity achieved by these and future vaccines would greatly facilitate the evaluation of different vaccine approaches. Functional human lymphoid xenografts have been established by transferring mature lymphoid cells to mice with severe combined immunodeficiency [hu-PBL-SCID mice (PBL, peripheral blood leukocyte) (10) (11) (12) ] or by grafting fetal lymphoid organs [SCID:hu mice (13) ] and such mice are susceptible to infection with HIV-1 (14, 15) . hu-PBL-SCID mice established by using tetanus-immune PBL donors produced a tetanus-specific secondary human antibody response (10), suggesting that hu-PBL-SCID mice derived from HIV-1 immune donors might mount a specific immune response to HIV-1. We have generated hu-PBL-SCID mice by using PBLs from donors immunized with 160-kDa glycoprotein (gpl60) subunit vaccines and challenged the resulting mice with a high dose of HIV-1. hu-PBL-SCID mice derived from three of four vaccinees who had been primed with recombinant vaccinia virus expressing gp160 and booster injected with recombinant gp160 protein (rgp160) were resistant to challenge with homologous strains of HIV-1. The level of immunity adoptively transferred to hu-PBL-SCID mice (i.e., the fraction of challenged mice resistant to infec- Table 2 and Fig. 1) . Accordingly, experimental groups in which <16% of mice were protected were classified as not different from controls (see Fig. 1 ). In addition, data from individual experiments were analyzed for significant differences from pooled controls by Fisher's exact test as indicated in Table 2 . HIV-1 Challenge of Vaccinee-Derived hu-PBL-SCID Mice. At the four intervals indicated in Table 1 , hu-PBL-SCID mice were derived by using PBLs from two to four donors. The results of the four separate experiments, performed at various intervals of time after the first or second round of injecting donors with rgpl60, are summarized in Table 2 and Fig. 1 . hu-PBL-SCID mice derived from donor 065 4 weeks after the initial booster regimen and donor 078 10 weeks after the initial booster dose with rgpl6O (Exp. 1) showed highly Table 1 . Stippled area at 0-16% protection represents the level of protection that would not differ significantly from hu-PBL-SCID mice established from control donors. gpl60 Ab, relative titer of antibody in a gpl60 ELISA (see Table 1 ); neut Ab, presence of HIV-1 neutralizing antibody; T prol, relative level of donor PBL proliferation after stimulation with gpl60. Proc. Natl. Acad. Sci. USA 90 (1993) significant (P < 0.05) resistance to infection after challenge with 104 tissue culture ID50 of HIV-1111B. After 41-47 weeks (Exp. 2), PBLs from donor 065 still retained the capacity to protect 50% of hu-PBL-SCID mice against viral challenge, but a protective response was no longer detected with PBLs from donor 078. Moreover, by 48-72 weeks (Exp. 3), no significant resistance to HIV-1 challenge was observed when PBLs from any of the four donors were transferred to SCID mice. PBLs obtained 5 weeks after a secondary gpl60 booster injection of donors 065, 078, and 033 (Exp. 4) transferred an augmented protective response compared to the results obtained in Exp. 3, which serves as a prebooster control, but fewer animals were protected than immediately after the initial gpl60 booster (Table 2) . No protection was observed in hu-PBL-SCID mice derived from similarly immunized donor 053 in this experiment, but this does not rule out a protective response after the initial rgpl60 booster (not tested). Moreover, this donor had lower antibody and T-cell proliferative responses than other donors to gp160 (Table 1) .
RESULTS

Status
Two groups of control hu-PBL-SCID mice were used in these experiments (Table 2 ). Mice derived from donors vaccinated with vaccinia alone, alum, or hepatitis vaccine (mock-vaccinated controls) were generated by the same protocol (including shipment of blood) as the hu-PBL-SCID mice derived from gpl60 vaccinees and had the same high rate of infection as control hu-PBL-SCID mice reconstituted from local, unimmunized donors, or as mice derived from PBLs obtained over a year after injecting with rgpl6O (Exp. 3). In addition, no significant differences in human serum immunoglobulin levels were noted between protected (mean + SE, 132 ± 28 ,ug/ml) and unprotected (181 ± 21 ug/ml) animals at the time of HIV-1 challenge. HIV-1-infected mice subsequently had lower immunoglobulin levels, as reported (15) . The results thus appear to reflect adoptive transfer of a protective human immune response and not technical variation in protocols or levels of human cell reconstitution.
Evidence for Partial Protection of Vaccinee-Derived hu-PBL-SCID Mice. The observed protection of some but not all HIV-1-challenged hu-PBL-SCID mice suggested that transferred immunity might be mediating some antiviral effect even in those animals from which HIV-1 was isolated. We therefore analyzed Exps. 3 (prebooster) and 4 (postbooster), which were identical in design except for the intervening secondary rgpl6O booster, in more detail. In PBL cocultures from hu-PBL-SCID mice in Exp. 3, high levels (>500 pg) of p24 antigen were detected in peritoneal lavage cells from 34 of 35 animals after 1 week of culture, whereas in Exp. 4, only 3 of 25 animals had virus detected in peritoneal lavage cells by 1 week of culture, and only 13 of 25 animals had detectable virus after 4 weeks of culture. No mice in Exp. 3 had virus isolated solely from spleen cells, while Exp. 4 had 4 mice in which virus was detected only in spleen cells and not in peritoneal cavity cells. These results suggest that adoptive transfer of PBLs from vaccinated donors to SCID mice had induced partial resistance to virus replication in mice that did become infected and that this resistance was more effective in the peritoneal cavity than in the spleen.
Correlation Between Donor Immune Status and Protection of hu-PBL-SCID Mice. We compared the percentage of each experimental group protected against HIV-1 challenge in all four experiments (Fig. 1) with the relative level of each of the donor immune responses measured (Table 1) Table 1 These studies have not attempted to define the mechanism responsible for the adoptively transferred resistance to HIV-1 infection. The fact that donors 065, 078, and 033 gave rise to HIV-resistant hu-PBL-SCID mice, yet only donor 078 had demonstrable neutralizing antibody levels, suggests that neutralizing antibody is not essential for protective HIV immunity in this model. The levels of total antibody reactive with gp160 also did not predict which SCID mice would resist infection (see Table 1 and Fig. 2) , with the highest antibody titers being found at times when only partial protection was observed. The T-cell proliferative response to gp160 of each donor did show a positive correlation (r = 0.755) with the level of protection, although the small number of observations (n = 6) limits the significance of this analysis (see Fig.  2 ). This correlation between T-cell proliferative responses and protection and the poor correlation between antibody levels and resistance to infection (r = 0.152; Fig. 2 ) suggest that cellular immune responses to HIV-1 should be given more emphasis in future vaccine development. Recent reports (22) (23) (24) have indicated that either vaccinia gp160 or rgpl6O immunization is sufficient to elicit virus-specific cytolytic T cells, which alone or in combination with other antigen-specific T-cell functions may have contributed to the protection observed in our experiments. Neutralizing antibody may correlate with the efficacy of candidate HIV-1 vaccines tested in other animal models but may not be sufficient for protection-e.g., macaques vaccinated with whole, inactivated simian immunodeficiency virus (SIV) developed neutralizing antibody titers of 1:8-1:128, yet none was able to resist challenge with live SIV (25) . Finally, we cannot rule out a role for nonspecific murine effector cells (e.g., natural killer cells or macrophages) in the antiviral effects observed in our experiments, although any such effect would have to depend on the level of transferred human immune function. Future studies in the hu-PBL-SCID model in which purified human effector populations and antibodies are evaluated should clarify these issues.
These experiments provide two sources of encouragement for development of vaccines against HIV. First, a significant level of protective immunity was demonstrable after immunization with HIV envelope proteins despite the absence of neutralizing antibody in most of the PBL donors. Second, these results support use of the hu-PBL-SCID model as a step in evaluation of vaccine approaches, both in evaluating responses of vaccinated individuals and in dissecting the immunological mechanisms involved in generating protective immunity.
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